Biomarkers for Non-Small Cell Lung Cancer: From the Bench to the Bedside
Lung cancer (LC) is inarguably one of the biggest battles to be fought in the field of oncology, and non-small cell lung cancer accounts for over 85% of all lung cancer cases [...]
Main Authors: | Ramon Andrade de Mello, Giovanna Araújo Amaral |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/10/3376 |
Similar Items
-
Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
by: Francesco Pelliccia, et al.
Published: (2022-08-01) -
Hypoxia and Cancer: From Bench to Bedside
by: Lingzhi Wang, et al.
Published: (2023-04-01) -
Biomarkers in Pediatric Nephrology—From Bedside to Bench and Back Again
by: Kinga Musiał
Published: (2022-10-01) -
CAR-T Cell Therapy: From the Bench to the Bedside
by: Vita Golubovskaya
Published: (2017-10-01) -
Galectins in Cancer and Translational Medicine: From Bench to Bedside
by: Armando Bartolazzi
Published: (2018-09-01)